OncoMatch/Clinical Trials/NCT06932562
A Study to Learn How Safe and How Well Linvoseltamab Works Compared to Standard Treatment in Adult Patients With Multiple Myeloma Who Are Not Eligible for Transplant
Is NCT06932562 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments including Linvoseltamab and Daratumumab for multiple myeloma.
Treatment: Linvoseltamab · Daratumumab · Lenalidomide · Dexamethasone — This study is researching an experimental drug called linvoseltamab. The study is focused on participants with newly diagnosed multiple myeloma (NDMM) who are ineligible for autologous stem cell transplantation (transplant-ineligible). The main purpose of this study is to compare the effect and safety of linvoseltamab with the effect and safety of the standard treatment.
Check if I qualifyExtracted eligibility criteria
Cancer type
Multiple Myeloma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: any prior therapy for MGUS, SMM, or MM
Exception: focal radiation and/or a short course of corticosteroids as defined in the protocol
Any prior therapy for monoclonal gammopathy of undetermined significance (MGUS), smoldering multiple myeloma (SMM), or MM, with the exception of: focal radiation and/or a short course of corticosteroids as defined in the protocol.
Cannot have received: investigational agent or cell therapy with known or suspected activity against MM
Participants who have received or are receiving any investigational agent or cell therapy with known or suspected activity against MM
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify